Study Summary
This trial is testing ziv-aflibercept given with pembrolizumab to see if it is safe and effective in treating patients with advanced solid tumors.
- Sarcoma
- Cutaneous Melanoma
- Malignant neoplasm of ovary
- Renal Cell Carcinoma
- Metastatic Colorectal Carcinoma
- Metastatic Malignant Solid Neoplasm
- Platinum-Resistant Ovarian Carcinoma
- Colorectal Carcinoma
- Recurrent Melanoma
- Pathologic Stage IV Cutaneous Melanoma AJCC v8
- Refractory Melanoma
- Refractory Renal Cell Carcinoma
- Metastatic Ovarian Carcinoma
- Metastatic Melanoma
- Metastatic Renal Cell Carcinoma ( mRCC)
- Stage IV Ovarian Cancer AJCC v8
- Stage IV Renal Cell Cancer AJCC v8
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 4 Secondary · Reporting Duration: Time from start of trial treatment to death from any cause, assessed up to 12 months
Trial Safety
Safety Progress
Trial Design
1 Treatment Group
Treatment (pembrolizumab and ziv-aflibercept)
1 of 1
Experimental Treatment
78 Total Participants · 1 Treatment Group
Primary Treatment: Ziv-Aflibercept · No Placebo Group · Phase 1
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:About The Reviewer
Michael Gill - B. Sc.
First Published: October 13th, 2021
Last Reviewed: November 26th, 2022
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
- Rahma, Osama E, Kevin Tyan, Anita Giobbie-Hurder, Andrew S Brohl, Philippe L Bedard, Daniel J Renouf, Elad Sharon, et al.. 2022. “Phase IB Study of Ziv-aflibercept Plus Pembrolizumab in Patients with Advanced Solid Tumors”. Journal for Immunotherapy of Cancer. BMJ. doi:10.1136/jitc-2021-003569.
- 2015. "Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02298959.